JPRN-UMIN000013588已完成2 期
Phase II trial of GDP therapy (gemcitabine, cisplatin and dexamethasone) in patients with refractory or recurrence non-Hodgkin's lymphoma having a history of more than 2 regimens. - Phase II trial of GDP therapy (gemcitabine, cisplatin and dexamethasone) in patients with refractory or recurrence non-Hodgkin's lymphoma having a history of more than 2 regimens.
Kyoto Prefectural University of Medicine Department of Hematology and Oncology,0 个研究点目标入组 30 人开始时间: 2014年4月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Interstitial pneumonitis or pulmonary fibrosis. 2. Prior radiotherapy for the lungs. 3. Uncontrollable diabetes. 4. Uncontrollable heat disease. 5. Uncontrollable infection. 6. History of severe drug allergy. 7. Severe renal disorder. 8. Large quantity of pleural, abdominal or cardiac effusion. 9. Positive for HBs antigen. 10. Positive for HCV antibody. 11. Severe mental disease. 12. Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval. 13. Women who are pregnant or breastfeeding. Men/women who are unwilling to avoid pregnancy. 14. Inadequate for study enrollment by the physician.
研究者
相似试验
已完成
1 期
phase I/II trial of Gemcitabine/CDDP/S-1 combination chemotherapy for locally advanced or metastatic biliary tract cancerocally advanced or metastatic biliary tract cancerJPRN-UMIN000007563Keio University, School of Medicine, Div. of Gastroenterology, Dept.of Internal Medicine36
尚未招募
2 期
A phase 2 trial of GN (gemcitabine + nedaplatin) therapy for advanced urothelial cancer patients with pre-treatment of cisplatin or carboplatin.urothelial cancerJPRN-UMIN000021298Yamagata University, Department of Urology62
已完成
不适用
Phase I/II clinical trila by gemcitabine+CDDP- or S-1- combined peptide vaccination for metastatic biliary tract cancersmetastatic biliary tract cancersJPRN-UMIN000004494Tohoku University Hospital22
进行中（未招募）
1 期
A Phase III Randomised Trial of Gemcitabine plus Docetaxel followed by Doxorubicin versus observation for uterus-limited, high grade uterine leiomyosarcomaPatients with high risk uterine LMS, FIGO stage I (confined to corpus +/- cervix).MedDRA version: 14.1 Level: PT Classification code 10046799 Term: Uterine leiomyosarcoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002852-17-GBEORTC216
招募中
2 期
Biliary tract cancer cross-over studybiliary tract cancerJPRN-jRCT1041230014Yamashita Tatsuya50